Atlantic Accelerator and DiagNodus Speed Development of Cancer Screening
DiagNodus Ltd, a Cambridge-based biomedical early-stage company developing a diagnostic solution for the early detection for colorectal cancer (CRC), has signed an agreement with Atlantic Accelerator (AA) to speed the route to market for DiagNodus’ innovative CRC screening technology – Screen2C™.
Following a competitive pitching round by worldwide healthcare ventures, DiagNodus was selected to join the AA fast-track programme with two AA members joining DiagNodus’ Board.
AA’s fast-track programme provides DiagNodus with the expertise, support and international networks to accelerate the development of and fundraising for Screen2C™, as well as to provide a greater scope for clinical trials, business partnerships and regulatory compliance—the necessary next steps for the early-stage company.
Download the press release here